
Caitlin Costello, MD, looks to the future of treating patients with relapsed/refractory multiple myeloma, highlighting potential opportunities and challenges in the therapeutic landscape.

Your AI-Trained Oncology Knowledge Connection!

Caitlin Costello, MD, is a hematologist and medical oncologist at the University of California, San Diego.

Caitlin Costello, MD, looks to the future of treating patients with relapsed/refractory multiple myeloma, highlighting potential opportunities and challenges in the therapeutic landscape.

A hematologist-oncologist provides clinical advice to community-based clinicians on key strategies for optimizing the treatment of patients with relapsed/refractory multiple myeloma.

Caitlin Costello, MD, provides clinical insights on best practices for treating patients with relapsed/refractory multiple myeloma who receive early-line CAR T-cell therapy and later relapse.

An expert on relapsed/refractory multiple myeloma discusses the role of stem cell transplantation in current treatment paradigms.

Following the recent approvals of ide-cel and cilta-cel CAR T-cell therapy for patients with relapsed/refractory multiple myeloma, a hematologist-oncologist discusses clinical research supporting their utilization.

Caitlin Costello, MD, presents the case of a 60-year-old woman with later relapsed/refractory multiple myeloma and discusses how the treatment landscape has evolved, highlighting remaining unmet needs.

Caitlin Costello, MD, discusses choosing the optimal first-line therapy for patients with multiple myeloma.